Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of GLS-5300, Administered ID Followed by CELLECTRA® 2000 (Electroporation, EP)

NCT03721718 is registered in ClinicalTrials.gov with GeneOne Life Science, Inc. as lead sponsor.

NCT NCT03721718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03721718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of GLS-5300, Administered ID Followed by CELLECTRA® 2000 (Electroporation, EP)
Lead sponsor
GeneOne Life Science, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
August 28, 2018
Completion date
April 22, 2020
Enrollment
60 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy